{
  "success": true,
  "pagesUsed": [
    1,
    4,
    9,
    10,
    15,
    16,
    17,
    18
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "PROTOCOL SUMMARY",
        "text": "PROTOCOL SUMMARY",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionTitle": "PROTOCOL SUMMARY",
        "sectionType": {
          "id": "a726b961-ef68-45ba-a5f6-c029380ee85b",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "SCHEDULE OF ACTIVITIES",
        "text": "SCHEDULE OF ACTIVITIES",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionTitle": "SCHEDULE OF ACTIVITIES",
        "sectionType": {
          "id": "1311a937-594b-4d13-80e2-adf76d18bbb0",
          "code": "Study Procedures",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Procedures",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_3",
        "name": "INTRODUCTION",
        "text": "INTRODUCTION",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "INTRODUCTION",
        "sectionType": {
          "id": "29b43bbb-6d54-43e0-adad-d907883fc440",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_3_1",
          "nci_3_2",
          "nci_3_3",
          "nci_3_4",
          "nci_3_5",
          "nci_3_6",
          "nci_3_7",
          "nci_3_8"
        ]
      },
      {
        "id": "nc_4",
        "name": "STUDY OBJECTIVES AND ENDPOINTS",
        "text": "STUDY OBJECTIVES AND ENDPOINTS",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "STUDY OBJECTIVES AND ENDPOINTS",
        "sectionType": {
          "id": "a544642d-1157-46aa-842d-78160680c337",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2",
          "nci_4_3",
          "nci_4_4",
          "nci_4_5",
          "nci_4_6",
          "nci_4_7",
          "nci_4_8",
          "nci_4_9",
          "nci_4_10"
        ]
      },
      {
        "id": "nc_5",
        "name": "STUDY DESIGN",
        "text": "STUDY DESIGN",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "STUDY DESIGN",
        "sectionType": {
          "id": "8b268338-d3a6-4e36-b958-0369e984b582",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_5_1",
          "nci_5_2"
        ]
      },
      {
        "id": "nc_6",
        "name": "REFERENCES",
        "text": "REFERENCES",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "16",
        "sectionTitle": "REFERENCES",
        "sectionType": {
          "id": "9abf7e91-5f38-4ffb-9d49-54fe9bdd1412",
          "code": "References",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "References",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_7",
        "name": "Abbreviations",
        "text": "Abbreviations",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 1",
        "sectionTitle": "Abbreviations",
        "sectionType": {
          "id": "56854852-7685-4e79-8542-30ac525454c0",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_3_1",
        "name": "Indication",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "Indication"
      },
      {
        "id": "nci_3_2",
        "name": "Background and Rationale",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "Background and Rationale"
      },
      {
        "id": "nci_3_3",
        "name": "Pneumococcal Disease",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.1",
        "sectionTitle": "Pneumococcal Disease"
      },
      {
        "id": "nci_3_4",
        "name": "Vaccines to Prevent Pneumococcal Disease",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2",
        "sectionTitle": "Vaccines to Prevent Pneumococcal Disease"
      },
      {
        "id": "nci_3_5",
        "name": "Pneumococcal Polysaccharide Vaccines",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2.1",
        "sectionTitle": "Pneumococcal Polysaccharide Vaccines"
      },
      {
        "id": "nci_3_6",
        "name": "Pneumococcal Polysaccharide Conjugate Vaccines",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2.2",
        "sectionTitle": "Pneumococcal Polysaccharide Conjugate Vaccines"
      },
      {
        "id": "nci_3_7",
        "name": "Rationale for 20vPnC and Study B7471007",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2.3",
        "sectionTitle": "Rationale for 20vPnC and Study B7471007"
      },
      {
        "id": "nci_3_8",
        "name": "Benefit-Risk Assessment",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.3",
        "sectionTitle": "Benefit-Risk Assessment"
      },
      {
        "id": "nci_4_1",
        "name": "Primary Safety Objective (All Cohorts)",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1",
        "sectionTitle": "Primary Safety Objective (All Cohorts)"
      },
      {
        "id": "nci_4_2",
        "name": "Primary Safety Endpoints (All Cohorts)",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1.1",
        "sectionTitle": "Primary Safety Endpoints (All Cohorts)"
      },
      {
        "id": "nci_4_3",
        "name": "Primary Immunogenicity Objectives – Cohort 1 (60 Years of Age and Older)",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2",
        "sectionTitle": "Primary Immunogenicity Objectives – Cohort 1 (60 Years of Age and Older)"
      },
      {
        "id": "nci_4_4",
        "name": "Primary Immunogenicity Endpoint – Cohort 1 (60 Years of Age and Older)",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2.1",
        "sectionTitle": "Primary Immunogenicity Endpoint – Cohort 1 (60 Years of Age and Older)"
      },
      {
        "id": "nci_4_5",
        "name": "Secondary Objective – Cohort 2 (50 Through 59 Years of Age)",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.3",
        "sectionTitle": "Secondary Objective – Cohort 2 (50 Through 59 Years of Age)"
      },
      {
        "id": "nci_4_6",
        "name": "Secondary Endpoint – Cohort 2 (50 Through 59 Years of Age)",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.3.1",
        "sectionTitle": "Secondary Endpoint – Cohort 2 (50 Through 59 Years of Age)"
      },
      {
        "id": "nci_4_7",
        "name": "Secondary Objective – Cohort 3 (18 Through 49 Years of Age)",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.4",
        "sectionTitle": "Secondary Objective – Cohort 3 (18 Through 49 Years of Age)"
      },
      {
        "id": "nci_4_8",
        "name": "Secondary Endpoint – Cohort 3 (18 Through 49 Years of Age)",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.4.1",
        "sectionTitle": "Secondary Endpoint – Cohort 3 (18 Through 49 Years of Age)"
      },
      {
        "id": "nci_4_9",
        "name": "Secondary Objective – All Cohorts",
        "text": "",
        "order": 8,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.5",
        "sectionTitle": "Secondary Objective – All Cohorts"
      },
      {
        "id": "nci_4_10",
        "name": "Secondary Endpoints – All Cohorts",
        "text": "",
        "order": 9,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.5.1",
        "sectionTitle": "Secondary Endpoints – All Cohorts"
      },
      {
        "id": "nci_5_1",
        "name": "Duration of Subject Participation",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "Duration of Subject Participation"
      },
      {
        "id": "nci_5_2",
        "name": "Duration of the Study",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "Duration of the Study"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "20vPnC",
        "expandedText": "20-valent Pneumococcal Conjugate Vaccine",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "MPA",
        "expandedText": "Medical Products Agency",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "EudraCT",
        "expandedText": "European Clinical Trials Database",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "AOM",
        "expandedText": "acute otitis media",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "PPSV23",
        "expandedText": "23-valent pneumococcal polysaccharide vaccine",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "CAP",
        "expandedText": "community-acquired pneumonia",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "13vPnC",
        "expandedText": "13-valent pneumococcal conjugate vaccine",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "CRM197",
        "expandedText": "cross-reactive material 197",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "VT",
        "expandedText": "vaccine-type",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "IPD",
        "expandedText": "invasive pneumococcal disease",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "e-diary",
        "expandedText": "electronic diary",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "SAEs",
        "expandedText": "serious adverse events",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 7,
      "itemCount": 20,
      "abbreviationCount": 12
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "20-valent Pneumococcal Conjugate Vaccine (20vPnC)",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "Final Protocol Amendment 2",
      "versionDate": "11 February 2019",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "20vPnC",
          "expansion": "20-valent Pneumococcal Conjugate Vaccine"
        },
        {
          "abbreviation": "MPA",
          "expansion": "Medical Products Agency"
        },
        {
          "abbreviation": "EudraCT",
          "expansion": "European Clinical Trials Database"
        },
        {
          "abbreviation": "AOM",
          "expansion": "acute otitis media"
        },
        {
          "abbreviation": "PPSV23",
          "expansion": "23-valent pneumococcal polysaccharide vaccine"
        },
        {
          "abbreviation": "CAP",
          "expansion": "community-acquired pneumonia"
        },
        {
          "abbreviation": "13vPnC",
          "expansion": "13-valent pneumococcal conjugate vaccine"
        },
        {
          "abbreviation": "CRM197",
          "expansion": "cross-reactive material 197"
        },
        {
          "abbreviation": "VT",
          "expansion": "vaccine-type"
        },
        {
          "abbreviation": "IPD",
          "expansion": "invasive pneumococcal disease"
        },
        {
          "abbreviation": "e-diary",
          "expansion": "electronic diary"
        },
        {
          "abbreviation": "SAEs",
          "expansion": "serious adverse events"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "20-valent Pneumococcal Conjugate Vaccine (20vPnC)",
        "version": "Final Protocol Amendment 2",
        "versionDate": "11 February 2019"
      },
      "sections": [
        {
          "number": null,
          "title": "PROTOCOL SUMMARY",
          "type": "Synopsis"
        },
        {
          "number": null,
          "title": "SCHEDULE OF ACTIVITIES",
          "type": "Study Procedures"
        },
        {
          "number": "1",
          "title": "INTRODUCTION",
          "type": "Introduction",
          "subsections": [
            {
              "number": "1.1",
              "title": "Indication"
            },
            {
              "number": "1.2",
              "title": "Background and Rationale"
            },
            {
              "number": "1.2.1",
              "title": "Pneumococcal Disease"
            },
            {
              "number": "1.2.2",
              "title": "Vaccines to Prevent Pneumococcal Disease"
            },
            {
              "number": "1.2.2.1",
              "title": "Pneumococcal Polysaccharide Vaccines"
            },
            {
              "number": "1.2.2.2",
              "title": "Pneumococcal Polysaccharide Conjugate Vaccines"
            },
            {
              "number": "1.2.2.3",
              "title": "Rationale for 20vPnC and Study B7471007"
            },
            {
              "number": "1.3",
              "title": "Benefit-Risk Assessment"
            }
          ]
        },
        {
          "number": "2",
          "title": "STUDY OBJECTIVES AND ENDPOINTS",
          "type": "Objectives",
          "subsections": [
            {
              "number": "2.1",
              "title": "Primary Safety Objective (All Cohorts)"
            },
            {
              "number": "2.1.1",
              "title": "Primary Safety Endpoints (All Cohorts)"
            },
            {
              "number": "2.2",
              "title": "Primary Immunogenicity Objectives – Cohort 1 (60 Years of Age and Older)"
            },
            {
              "number": "2.2.1",
              "title": "Primary Immunogenicity Endpoint – Cohort 1 (60 Years of Age and Older)"
            },
            {
              "number": "2.3",
              "title": "Secondary Objective – Cohort 2 (50 Through 59 Years of Age)"
            },
            {
              "number": "2.3.1",
              "title": "Secondary Endpoint – Cohort 2 (50 Through 59 Years of Age)"
            },
            {
              "number": "2.4",
              "title": "Secondary Objective – Cohort 3 (18 Through 49 Years of Age)"
            },
            {
              "number": "2.4.1",
              "title": "Secondary Endpoint – Cohort 3 (18 Through 49 Years of Age)"
            },
            {
              "number": "2.5",
              "title": "Secondary Objective – All Cohorts"
            },
            {
              "number": "2.5.1",
              "title": "Secondary Endpoints – All Cohorts"
            }
          ]
        },
        {
          "number": "3",
          "title": "STUDY DESIGN",
          "type": "Study Design",
          "subsections": [
            {
              "number": "3.1",
              "title": "Duration of Subject Participation"
            },
            {
              "number": "3.2",
              "title": "Duration of the Study"
            }
          ]
        },
        {
          "number": "16",
          "title": "REFERENCES",
          "type": "References"
        },
        {
          "number": "Appendix 1",
          "title": "Abbreviations",
          "type": "Appendix"
        }
      ]
    }
  }
}